Lebwohl, Mark (2020), "Supplement for "Twice-weekly topical calcipotriene / betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)""

Supplementary material A presents the trial design and interventions of the PSO-LONG trial.
Supplementary material B provides an overview of adverse events adjudicated as related to long-term corticosteroid use.
Supplementary material C details the list of Principal Investigators who supported with the study.